Facial Expression Recognition and Mirror Neurons in Parkinson's Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-07-31

Study Completion Date

2013-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

After few years of evolution, patients with Parkinson's disease may develop apathy, with different degrees of severity. Apathy is characterized by a loss of interest for the others and for activities. The lack of social interactions in these patients may be due to an impairment in decoding emotional facial expression. Indeed, facial expression recognition, which is necessary to understand other's emotional state, requires a subclinical facial mimicking of the expression observed. Yet, one of the clinical signs of PD is amimia.

This study aims to determinate if there is a facial mimicry disorder in PD ( Parkinson's disease )patients with emotional facial expression (EFE) recognition impairment, compared to healthy control subjects. We also want to know if this facial mimicry disorder is primary (subtended by facial mobility impairment, that is to say amimia) or secondary (related to the mirror neuron systems that allows us to activate similar neural networks when observing and feeling a specific emotion)

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Brain Mechanisms of Social Perception in Parkinson's Disease

NCT06884722

Social Perception in Parkinson's Disease

RECRUITING NA

Role of Deep Brain Stimulation on Social Cognition in Parkinsonian Patients

NCT03004573

Parkinson Disease

COMPLETED NA

Assessment of Three-dimensional Vision Alteration in Parkinson Disease

NCT01620164

Parkinson Disease

COMPLETED NA

Study of Eye Movements (EYE) as Early Markers of Brain Dysfunction (BRAIN) in Parkinson's Disease (PARK)

NCT04212637

Parkinson Disease

UNKNOWN NA

Visual Selective Attention in Parkinson's Disease

NCT01135407

Visual Attention in Parkinson's Disease

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

20 patients with an Idiopathic Parkinson's disease

\+ 20 paired healthy volunteers (on sex, age, and education)

After inclusion, patients are evaluated two times: they are studied without medication (MED OFF) and with medication (STIM ON) in a randomized order. The 2 evaluations should be spaced out 15 days to one month (J0 and J+15d)

Healthy subjects have only one visit J0 (inclusion and emotional facial expression recognition tests are made at the same time)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson's Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Emotional facial expression recognition tests

20 patients with an Idiopathic Parkinson's disease

\+ 20 paired healthy volunteers (on sex, age, and education)

After inclusion, patients are evaluated two times: they are studied without medication (MED OFF) and with medication (STIM ON) in a randomized order. The 2 evaluations should be spaced out 15 days to one month (J0 and J+15d)

Healthy subjects have only one visit J0 (inclusion and emotional facial expression recognition tests are made at the same time)

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with idiopathic Parkinson's disease according to UKPDSBB criteria - Men or women aged between 18 to 75 years
* Free from any visio-perceptive disorder (visual acuity and Vitec)
* Affiliated to National Health system
* Having given their informed consent

--Healthy controls
* Men or women aged between 18 to 75 years
* Free from any visio-perceptive disorder (visual acuity and Vitec)
* Affiliated to National Health system
* Having given their informed consent

Exclusion Criteria

* With dementia or with significant dysexecutive disorder (MMS \<24, MATTIS\< 130)
* With fluctuations (\<5 Levodopa intakes / day)
* With severe depression (BDI \> 27)
* With psychiatric comorbidities (hallucinations, psychos) evaluated with l'Unified Parkinson's disease Rating Scale part I (UPDRS part I =0)
* With faces processing disorder (Benton \< 39)
* Pregnant
* Treatment with deep brain stimulation
* Under guardianship
* In excluding period for another study

--Healthy controls
* Suffering of neurological or psychiatric evolutive condition
* With severe depression (BDI \> 27)
* With faces processing disorder (Benton \< 39)
* Pregnant
* In excluding period for another study

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes